A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors

Exclusion Criteria

• •1. Known central nervous system malignancy.
• •2. Gastrointestinal disease that may interfere with drug absorption.
• •3. Significant cardiovascular disease.
• •4. Significant ECG abnormalities.
• •5. Ongoing risk of bleeding due to active peptic ulcer disease, bleeding diathesis, or requirement for systemic anticoagulants. Use of heparin or thrombolytic agents for local maintenance or clearance of a central venous catheter is permitted.
• •6. Ongoing systemic bacterial, fungal or viral infection (with the exception of fungal infections of the skin or nails).
• •7. Pregnancy or breastfeeding.
• •8. Major surgery within 4 weeks before the start of study therapy.
• •9. Prior solid organ or bone marrow progenitor cell transplantation.
• •10. Prior therapy with any known inhibitor of MNK1 or MNK2.
• •11. Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids (can be using topical or inhaled corticosteroids).
• •12. Use of drugs that might pose a risk of a drug-drug interaction within 4-7 days before the start of study therapy.